Cadrenal Therapeutics, Inc. (CVKD)

Market Cap	22.83M
Revenue (ttm)	n/a
Net Income (ttm)	-14.39M
Shares Out	2.08M
EPS (ttm)	-8.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,988
Open	11.34
Previous Close	11.00
Day's Range	10.83 - 11.44
52-Week Range	8.12 - 22.90
Beta	1.10
Analysts	Strong Buy
Price Target	32.00 (+190.91%)
Earnings Date	Nov 10, 2025

About CVKD

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agre...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 20, 2023
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: CVKD
• Website: https://www.cadrenal.com

Analyst Summary

According to one analyst, the rating for CVKD stock is "Strong Buy" and the 12-month stock price target is $32.0.

Price Target

$32.0

(190.91% upside)

Analyst Consensus: Strong Buy